CATHENA — CANCER THERAPY BY NANOMEDICAL (Q2034011): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
||
| Property / financed by | |||
| Property / financed by: Directorate-General for Regional and Urban Policy / rank | |||
Revision as of 07:47, 2 November 2020
Project Q2034011 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CATHENA — CANCER THERAPY BY NANOMEDICAL |
Project Q2034011 in Italy |
Statements
79,363.46 Euro
0 references
158,726.91 Euro
0 references
50.0 percent
0 references
10 November 2017
0 references
30 June 2021
0 references
BRACCO IMAGING SPA
0 references
45°40'37.52"N, 13°45'12.31"E
0 references
AD OGGI LA LOTTA CONTRO I TUMORI RIMANE UNO DELLE MAGGIORI TEMATICHE DA AFFRONTARE A LIVELLO MONDIALE. LE TERAPIE FARMACOLOGICHE AVANZATE ATTUALMENTE PIù UTILIZZATE SONO BASATE SU ANTICORPI DIRETTI VERSO SPECIFICI BERSAGLI BIOMOLECOLARI ALLO SCOPO DI CONTRASTARE I PROCESSI METABOLICI DI PROLIFERAZIONE TUMORALE O PER INDURRE LA MORTE DELLE CELLULE TUMORALI. RECENTEMENTE SONO STATI IMMESSI SUL MERCATO FARMACI BASATI SU SISTEMI NANODIMENSIONALI PIù COMUNEMENTE NOTI CON IL TERMINE NANOMEDICINE. L (Italian)
0 references
TO DATE, THE FIGHT AGAINST CANCER REMAINS ONE OF THE MAJOR CHALLENGES FACING THE WORLD. ADVANCED DRUG THERAPIES, WHICH ARE CURRENTLY USED, ARE BASED ON ANTIBODIES DIRECTED AT SPECIFIC BIOMOLECULAR TARGETS TO COUNTER THE METABOLIC PROCESSES OF TUMOUR GROWTH OR TO INDUCE THE CANCER CELLS TO DIE. RECENTLY, MEDICINAL PRODUCTS BASED ON NANODIMENSIONAL SYSTEMS ARE COMMONLY KNOWN AS NANOMEDICAL. L (English)
0 references
Identifiers
D91B19000180007
0 references